European regulators find deficiencies at Ranbaxy India plant, say no health riskReprints
European regulators said medicines produced at Ranbaxy Laboratories Ltd.'s Toansa facility in India posed no risk to health despite identifying some manufacturing deficiencies, Reuters reported.
The European Medicines Agency said "there was no evidence" that medicines in the European market "that have an active pharmaceutical ingredient manufactured in Toansa were of unacceptable quality." The U.S. Food and Drug Administration recently banned the firm from exporting drugs produced at the facility "to prevent substandard quality products from reaching U.S. consumers."